US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

1.18

-0.0800-6.35%

Pre-market: 1.240.0600+5.08%04:00 EDT

Volume:93.56K

Turnover:111.65K

Market Cap:28.23M

PE:-1.21

High:1.25

Open:1.23

Low:1.16

Close:1.26

52wk High:9.22

52wk Low:1.16

Shares:23.93M

Float Shares:8.57M

Volume Ratio:0.69

T/O Rate:1.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9775

EPS(LYR):-1.0574

ROE:-553.75%

ROA:-203.78%

PB:7.46

PE(LYR):-1.12

Loading ...

Overview Company News Filings

Actuate Therapeutics’ Elraglusib Selected for Evaluation in Beacon2 Trial for High-Risk Pediatric Neuroblastoma

THOMSON REUTERS

Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics posts ASCO presentation on elraglusib plus chemotherapy in metastatic pancreatic cancer

Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer

Actuate Therapeutics Announces Asco Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor

Actuate Therapeutics shareholders elected two directors at annual meeting

Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Actuate Therapeutics Q1 net loss narrows 10.94% to $5.63 million

Actuate Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)

Actuate Therapeutics receives FDA clearance for oral elraglusib study

Actuate Therapeutics adds Martin Huber to board of directors

Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial

Actuate Therapeutics Inc - FDA Clears Ind for Phase 1/2 Study of Oral Elraglusib in Advanced Cancer Patients

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":1.18,"timestamp":1784923200000,"preClose":1.26,"halted":0,"volume":93561,"hourTrading":{"tag":"盘前","latestPrice":1.24,"preClose":1.18,"latestTime":"04:00 EDT","volume":1,"amount":1.24,"timestamp":1785139203402,"change":0.06,"changeRate":0.050847,"amplitude":0},"delay":0,"changeRate":-0.06349206349206354,"floatShares":8571600,"shares":23925852,"eps":-0.977528,"marketStatus":"Pre-Mkt","change":-0.08,"latestTime":"07-27 04:56:03 EDT","open":1.23,"high":1.25,"low":1.16,"amount":111653.29288230001,"amplitude":0.071429,"askPrice":1.36,"askSize":100,"bidPrice":0.9786,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.977528,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785159000000},"marketStatusCode":1,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":1.18,"preHourTrading":{"tag":"盘前","latestPrice":1.24,"preClose":1.18,"latestTime":"04:00 EDT","volume":1,"amount":1.24,"timestamp":1785139203402,"change":0.06,"changeRate":0.050847,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.18,"preClose":1.18,"latestTime":"19:34 EDT","volume":576,"amount":680.397,"timestamp":1784936050208,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6894145496816868},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":8571600,"roa":"-203.78%","roe":"-553.75%","lyrEps":-1.05737,"volumeRatio":0.6894145496816868,"shares":23925852,"dividePrice":0,"high":1.25,"amplitude":0.071429,"preClose":1.26,"low":1.16,"week52Low":1.16,"pbRate":"7.46","week52High":9.22,"institutionHeld":0,"latestPrice":1.18,"eps":-0.977528,"divideRate":0,"volume":93561,"delay":0,"ttmEps":-0.977528,"open":1.23,"prevYearClose":6.12,"prevWeekClose":1.18,"prevMonthClose":1.53,"prevQuarterClose":1.53,"fiveDayClose":1.44,"twentyDayClose":1.96,"sixtyDayClose":2.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"ACTU","fiscalQuarterEnding":"2026/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2026-03-26","symbol":"ACTU","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1756180800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-07-24","current":-1.207127,"percent":0.995943,"low":-9.225925,"twenty":-6.484054,"median":-5.540019,"eighty":-3.587625,"high":-1.344238,"avg":-5.163197,"sd":1.646146,"marketCap":30146573},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176},{"date":"2026-02-13","current":-4.085894,"twenty":-6.675886,"median":-5.86386,"eighty":-5.121593,"marketCap":98551710},{"date":"2026-02-20","current":-4.085894,"twenty":-6.6744,"median":-5.836285,"eighty":-5.109147,"marketCap":98551710},{"date":"2026-02-27","current":-3.806434,"twenty":-6.670885,"median":-5.810835,"eighty":-5.051947,"marketCap":91811145},{"date":"2026-03-06","current":-3.083693,"twenty":-6.66337,"median":-5.801368,"eighty":-5.014488,"marketCap":74378649},{"date":"2026-03-13","current":-2.457318,"twenty":-6.638594,"median":-5.7914,"eighty":-4.984609,"marketCap":59270486},{"date":"2026-03-20","current":-2.409136,"twenty":-6.610668,"median":-5.770478,"eighty":-4.925104,"marketCap":58108320},{"date":"2026-03-27","current":-2.421357,"twenty":-6.609918,"median":-5.754096,"eighty":-4.858871,"marketCap":53821570},{"date":"2026-04-02","current":-2.656026,"twenty":-6.605591,"median":-5.74824,"eighty":-4.848283,"marketCap":59037758},{"date":"2026-04-10","current":-2.016167,"twenty":-6.591355,"median":-5.726634,"eighty":-4.839764,"marketCap":44815069},{"date":"2026-04-17","current":-2.293524,"twenty":-6.585305,"median":-5.718473,"eighty":-4.830404,"marketCap":50980105},{"date":"2026-04-24","current":-2.698891,"twenty":-6.578607,"median":-5.699843,"eighty":-4.807832,"marketCap":59990542},{"date":"2026-05-01","current":-3.13626,"twenty":-6.553112,"median":-5.691423,"eighty":-4.789745,"marketCap":69712330},{"date":"2026-05-08","current":-3.562962,"twenty":-6.537578,"median":-5.687496,"eighty":-4.757961,"marketCap":79197001},{"date":"2026-05-15","current":-3.221727,"twenty":-6.536778,"median":-5.667354,"eighty":-4.71569,"marketCap":69384970},{"date":"2026-05-22","current":-2.688476,"twenty":-6.532441,"median":-5.647014,"eighty":-4.678926,"marketCap":57900561},{"date":"2026-05-29","current":-2.310756,"twenty":-6.527901,"median":-5.644452,"eighty":-4.628468,"marketCap":49765772},{"date":"2026-06-05","current":-2.155224,"twenty":-6.519006,"median":-5.637377,"eighty":-4.558084,"marketCap":46416152},{"date":"2026-06-12","current":-2.210771,"twenty":-6.519006,"median":-5.632466,"eighty":-4.465658,"marketCap":47612445},{"date":"2026-06-18","current":-2.277428,"twenty":-6.511576,"median":-5.624712,"eighty":-4.24967,"marketCap":49047996},{"date":"2026-06-26","current":-2.177443,"twenty":-6.50229,"median":-5.608839,"eighty":-4.114631,"marketCap":46894669},{"date":"2026-07-02","current":-1.599754,"twenty":-6.493669,"median":-5.581175,"eighty":-4.09553,"marketCap":34453226},{"date":"2026-07-10","current":-1.366457,"twenty":-6.488137,"median":-5.560665,"eighty":-4.043493,"marketCap":29428797},{"date":"2026-07-17","current":-1.844161,"twenty":-6.487388,"median":-5.541012,"eighty":-3.870035,"marketCap":39716914},{"date":"2026-07-24","current":-1.399785,"twenty":-6.484054,"median":-5.540019,"eighty":-3.587625,"marketCap":30146573}],"updateTime":1785102828783},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642287462","title":"Actuate Therapeutics’ Elraglusib Selected for Evaluation in Beacon2 Trial for High-Risk Pediatric Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642287462?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005533,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nFWN42H0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462256","title":"Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462256","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462256?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005526,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics’ elraglusib was selected for evaluation in BEACON2, a European Phase 1/2 platform trial in relapsed or refractory pediatric neuroblastoma.The study will test elraglusib with dinutuximab beta and chemotherapy, starting with a dose-confirmation stage focused on safety and dose selection.No BEACON2 results have been presented; data will be generated in the trial as it progresses.Prior early-stage clinical findings were previously reported, including a complete response in a heavily pretreated neuroblastoma patient in a separate Phase 1/2 study.The move expands elraglusib’s pediatric development path, supported by an FDA Rare Pediatric Disease designation for neuroblastoma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL2TySKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014021.USD","BK4139","ACTU","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4112","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462229","title":"Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462229","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462229?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005500,"startTime":"0","endTime":"0","summary":"- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham- Elraglusib wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308735/0/en/Actuate-Therapeutics-Elraglusib-Selected-for-Evaluation-in-BEACON2-Trial-for-High-Risk-Pediatric-Neuroblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4218","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","LU1093756325.SGD","IE00B5TLWC47.USD","BK4181","PK","LU1721428933.USD","BK4121","ACTU","LU0347712357.USD","LU2211817866.USD","BK4585","BK4567","BK4139","MTD","LU2413666426.HKD","LU1093756168.USD","BK4588","LU2413666699.HKD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640463409","title":"Actuate Therapeutics posts ASCO presentation on elraglusib plus chemotherapy in metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640463409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640463409?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:41","pubTimestamp":1780407713,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics published a post-hoc efficacy and biomarker analysis from its phase 2 1801 Part 3B study in first-line metastatic pancreatic cancer.Landmark analysis in patients completing at least one cycle showed median overall survival of 12.5 months with elraglusib plus chemotherapy vs 8.5 months with chemotherapy alone.Subgroup results showed longer survival signals in patients with baseline albumin ≥3 g/dL or CA19-9 <8,000 U/mL on the elraglusib regimen.Exploratory biomarker work linked KRAS, TP53, CDKN2A, or SMAD4 alterations to worse survival only in the elraglusib arm.Outcomes appeared stronger in Europe than North America, with early mortality of 5.3% vs 15.4% in the elraglusib arm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1zZLg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640220955","title":"Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640220955","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640220955?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:05","pubTimestamp":1780311945,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics reported Phase 2 elraglusib data in first-line metastatic pancreatic cancer at the 2026 ASCO Annual Meeting.Post-hoc analyses indicated longer survival in selected biomarker-defined patients receiving elraglusib with standard chemotherapy versus chemotherapy alone.A separate Phase 2 study suggested added clinical benefit when elraglusib was combined with FOLFIRINOX, with responses appearing deeper and more durable.Safety appeared manageable across regimens, supporting further development and potential positioning of elraglusib as a combination backbone therapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLbBm954:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","BK4112","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","SG9999014021.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","ACTU","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955964","title":"Actuate Therapeutics Announces Asco Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955964?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:00","pubTimestamp":1780311602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUAW3TV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640407955","title":"Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640407955","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640407955?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:00","pubTimestamp":1780311600,"startTime":"0","endTime":"0","summary":"- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/Actuate-Therapeutics-Announces-ASCO-Poster-Presentations-Demonstrating-Compelling-Clinical-and-Biomarker-Data-for-Elraglusib-in-First-Line-Metastatic-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347120","title":"Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347120","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347120?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:24","pubTimestamp":1779488665,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) has issued an update. On May 21, 2026, Actuate Therapeutics, Inc. held its virtual Annual Meeting of Stockho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-stockholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-stockholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637344784","title":"Actuate Therapeutics shareholders elected two directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637344784","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637344784?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:44","pubTimestamp":1779482668,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics held its annual stockholder meeting on May 21, 2026.Stockholders elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes to the board.Crowe LLP’s appointment as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026 was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL9cBQ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636003336","title":"Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636003336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636003336?lang=en_us&edition=fundamental","pubTime":"2026-05-19 01:57","pubTimestamp":1779127020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 13:57 ET (17:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636003591","title":"Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2636003591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636003591?lang=en_us&edition=fundamental","pubTime":"2026-05-19 01:55","pubTimestamp":1779126925,"startTime":"0","endTime":"0","summary":"Lucid Capital lowered the firm’s price target on Actuate Therapeutics (ACTU) to $5 from $6 and keeps a Buy rating on the shares. The firm updated t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-price-target-lowered-to-5-from-6-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-price-target-lowered-to-5-from-6-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCID","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636247180","title":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636247180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636247180?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:20","pubTimestamp":1779099611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","XBI","ACTU","BK4581","BK4137","LABU","BK4139","LU0029874061.USD","XLV","PYXS","BK4588","LU0128526141.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581830","title":"Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581830?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:01","pubTimestamp":1778878868,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryActuate Therapeutics Inc ACTU.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ende","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S25P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710728","title":"Actuate Therapeutics Q1 net loss narrows 10.94% to $5.63 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710728","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710728?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:02","pubTimestamp":1778788969,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics posted a net loss of $5.63 million for the quarter ended March 31, 2026, narrowing from $6.32 million a year earlier.Operating loss improved to $5.71 million as total operating expenses fell to $5.71 million from $6.37 million.Research and development expense dropped to $2.57 million from $3.22 million, due to lower external clinical study costs and lower CMC spending.Pipeline update: FDA cleared a Phase 1/2 study for the oral elraglusib tablet following an IND filing in April 2026, while updated Phase 2 mPDAC data presented in January 2026 showed median overall survival of 10.1 months with elraglusib plus GnP versus 7.2 months for GnP alone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL7vnH4n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758989","title":"Actuate Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758989","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758989?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:03","pubTimestamp":1778702585,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Actuate Therapeutics Inc ACTU.OQ ACTU.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278805","title":"Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278805?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:20","pubTimestamp":1778667636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-actuate-therapeutics-inc-actu-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-actuate-therapeutics-inc-actu-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","BK4112","AGIO","BK4137","BK4139","BK4585","BLSG","LABU","ACTU","BLSX","XBI","LU0029874061.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634287109","title":"Actuate Therapeutics receives FDA clearance for oral elraglusib study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634287109","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634287109?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:55","pubTimestamp":1778507748,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced the FDA has cleared its investigational new drug application to conduct a Phase 1/2 study of oral elraglusib ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-receives-fda-clearance-for-oral-elraglusib-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-receives-fda-clearance-for-oral-elraglusib-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","ACTU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634283487","title":"Actuate Therapeutics adds Martin Huber to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634283487","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634283487?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:16","pubTimestamp":1778498173,"startTime":"0","endTime":"0","summary":"Huber is a board member at Syndax Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL275FtH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634880962","title":"Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634880962","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634880962?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:04","pubTimestamp":1778497477,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics received FDA clearance of an IND for oral elraglusib.Phase 1/2 trial in advanced solid tumors planned to start in 2H 2026, targeting higher drug exposure than IV formulation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8sjZ8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014021.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210149790.SGD","BK4112","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4585","BK4139","LU2095319765.USD","SG9999014013.SGD","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288486","title":"Actuate Therapeutics Inc - FDA Clears Ind for Phase 1/2 Study of Oral Elraglusib in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288486?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUAFKBM0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}